COMMUNIQUÉS West-GlobeNewswire

Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

14/05/2024 - 22:15

Vincerx continued to progress Phase 1 dose-escalation studies for VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC), and VIP236, a first-in-class small molecule-drug conjugate (SMDC) The [...]

Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results

14/05/2024 - 22:15

Outcome from End-of-Phase 2 Meeting Supportive of a Placebo-Controlled Phase 3 Trial Updated 12 and 24-Month Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials Continue to Show Oral LUM-201 Achieves Significant [...]

NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer

14/05/2024 - 22:15

PARIS and CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic [...]

NANOBIOTIX annonce l'acceptation par l'Agence américaine du médicament, la FDA, d'un protocole pour une nouvelle étude randomisée de Phase 2 évaluant NBTXR3 pour les patients atteints d'un cancer du poumon de stade trois

14/05/2024 - 22:15

PARIS et CAMBRIDGE, Mass., 14 mai 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ : NBTX – la « Société »), société française de biotechnologie en phase de développement clinique avancé, pionnière des [...]

CooperCompanies to Participate in the William Blair Growth Stock Conference

14/05/2024 - 22:15

SAN RAMON, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, will participate in the William Blair Growth Stock Conference on Wednesday, June 5, 2024. Dan [...]

GENFIT Reports First Quarter 2024 Financial Information

14/05/2024 - 22:10

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 14, 2024 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients [...]

GENFIT : Information financière du premier trimestre 2024

14/05/2024 - 22:10

Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 14 mai 2024 – GENFIT (Nasdaq et Euronext : GNFT) , société biopharmaceutique de stade clinique avancé engagée dans l’amélioration de la vie des [...]

BioRestorative Therapies Provides First Quarter 2024 Business Update

14/05/2024 - 22:10

MELVILLE, N.Y., May 14, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a clinical stage company focused on stem cell-based therapies, today [...]

BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress

14/05/2024 - 22:05

Ozuriftamab vedotin (CAB-ROR2-ADC) Phase 2 data in squamous cell carcinoma of the head and neck (SCCHN) showed multiple confirmed responses and manageable safety profile; anticipate FDA meeting for SCCHN potential [...]

Singular Genomics Reports Recent Highlights and First Quarter 2024 Financial Results

14/05/2024 - 22:05

SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and [...]

QIAGEN receives European IVDR certification for QIAGEN Clinical Insight Interpret, its medical device software for clinical decision support

14/05/2024 - 22:05

As the first NGS interpretation platform for both oncology and hereditary applications, the updated version of QIAGEN Clinical Insight Interpret is approved for diagnostic use // Regulatory framework ensures greater [...]

Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

14/05/2024 - 22:05

Announced positive proof of concept data from Phase 1 clinical trial of ELVN-001 in CML, achieving an initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients Strong balance sheet with $321 [...]

Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

14/05/2024 - 22:05

Initial Data from Ongoing MyPEAK™ - 1 Phase 1b of TN-201 Expected in Second Half of 2024 Clinical Sites Activated for RIDGE ™ -1 Phase 1b Clinical Trial of TN-401 Announced Cost Containment Measures in Alignment with [...]

SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update

14/05/2024 - 22:05

- Announced Independent Data Monitoring Committee’s (IDMC) Recommendation to Continue the Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia (AML) Without Modifications: IDMC to Reconvene in June - - Completed [...]

ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2024

14/05/2024 - 22:05

PORTLAND, Maine, May 14, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and [...]

Asensus Surgical, Inc. Reports Operating and Financial Results for the First Quarter 2024

14/05/2024 - 22:05

RESEARCH TRIANGLE PARK, N.C., May 14, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical , Inc. (NYSE American: ASXC), a global leader of innovative digital solutions for the operating room, announced its operating and financial [...]

Vivos Therapeutics Reports First Quarter 2024 Financial Results and Provides Operational Update

14/05/2024 - 22:05

Vivos Expanding its Revenue Generating Initiatives As Operating Expenses Decrease 22%, Representing Seven Consecutive Quarters of Year Over Year Improvement Due to Successful Cost Cutting Initiatives Management to Host [...]

Longeveron Announces First Quarter 2024 Financial Results and Provides Business Update

14/05/2024 - 22:05

Phase 2b clinical trial evaluating Lomecel-B TM in rare pediatric disease HLHS on track for completing enrollment by end of 2024 Data from Phase 2a clinical trial evaluating Lomecel-B TM in Alzheimer’s Disease selected [...]

Iridex Reports First Quarter 2024 Financial Results

14/05/2024 - 22:05

MOUNTAIN VIEW, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for [...]